Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, April 21, 2023 -- Passage Bio, Inc. , a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced... | April 21, 2023

Related Keywords

University Of Pennsylvania ,Pennsylvania ,United States ,Philadelphia ,Stuart Henderson ,Mike Beyer ,University Of Pennsylvania Gene Therapy Program ,Healthcare Communications ,Passage Bio Inc ,Nasdaq ,Sam Brown Inc ,Nasdaq Listing Rule ,Passage Bio ,Inducement Options ,Gene Therapy Program ,Bio Investors ,Bio Media ,Nc Stock Exchange ,News ,Information ,Press Release ,Pril ,023 ,Massage ,Enetic ,Medicines ,Company ,Ocused ,N ,Developing ,Ransformative ,Therapies ,Or ,Central ,Nervous ,System ,Oday Pasg Us7027121000 ,